by CN Bio. | Oct 5, 2021 | Press releases
New Oncology Service supports unique in vitro investigations into the PK/PD relationship Harnesses CN Bio’s proprietary PhysioMimix™ PK system Represents first implementation of intellectual property licensed from Vanderbilt University to provide human-relevant...
by CN Bio. | Sep 15, 2021 | Blog
Drug discovery should be simple. Deliver the right molecule, antibody, new modality, or cell to the right target within the right organ at the right concentration. Once you have ensured there are no unwanted effects elsewhere in the body, you have developed a safe and...
by CN Bio. | Jul 27, 2021 | Press releases
Enables accurate modelling of the human colon and the mucosal barrier Provides new insights to the relationship between human microbiome and effect on human health Model to be integrated into CN Bio’s PhysioMimix™ OOC range of single- and multi-organ...
by CN Bio. | Jul 19, 2021 | Press releases
Lonza and CN Bio Announce Distribution Agreement Providing Prevalidated Hepatocytes for Use on Innovative Organ-on-a-chip Range Through a new distribution agreement, Lonza will supply a selection of cells to be prequalified for use in CN Bio’s innovative PhysioMimixTM...
by CN Bio. | Jul 15, 2021 | OOC Blog
The aim of organ-on-a-chip (OOC) technology is to more accurately replicate human physiology in vitro to overcome the relevance limitations of current approaches, and the field is progressing at a rapid pace! Many hundreds of academic researchers are choosing to work...
